Friday, April 13, 2012

Hyperion Therapeutics Files For IPO

South San Francisco-based Hyperion Therapeutics has filed for an IPO, saying that it is looking to raise up to $57.5M in an IPO on the NASDAQ Global Market. The firm has applied to list as HPTX. Hyperion is a developer of biopharmaceuticals aimed at orphan diseases and hepatology; the firm's lead compounds are aimed at treating urea cycle disorders (UCD) and hepatic encephalopathy (HE). The IPO is being underwritten by Leerink Swann, Cowen and Company, and Needham & Company. The company is venture backed by Bay City Capital, Highland Capital Partners, Panorama Capital, New Enterprise Associates, Sofinnova Venture Partners, and Ucyclyd Pharma. The firm is pre-revenue.